MCID: DMY001
MIFTS: 46

Demyelinating Polyneuropathy

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Demyelinating Polyneuropathy

MalaCards integrated aliases for Demyelinating Polyneuropathy:

Name: Demyelinating Polyneuropathy 12 14
Peripheral Demyelinating Neuropathy 12 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5214
NCIt 46 C27062
SNOMED-CT 64 23414001
UMLS 69 C0270922

Summaries for Demyelinating Polyneuropathy

MalaCards based summary : Demyelinating Polyneuropathy, also known as peripheral demyelinating neuropathy, is related to chronic inflammatory demyelinating polyneuropathy and guillain-barre syndrome. An important gene associated with Demyelinating Polyneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Neuroscience and L1CAM interactions. The drugs Antibodies and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, spinal cord and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Demyelinating Polyneuropathy

Diseases in the Demyelinating Polyneuropathy family:

Chronic Inflammatory Demyelinating Polyneuropathy Subacute Inflammatory Demyelinating Polyneuropathy

Diseases related to Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 200)
# Related Disease Score Top Affiliating Genes
1 chronic inflammatory demyelinating polyneuropathy 33.6 AIF1 CNTN2 HP NFASC TTR
2 guillain-barre syndrome 32.3 ALB HP PMP22
3 polyneuropathy 32.0 MAG PMP22 TTR
4 multifocal motor neuropathy 30.5 CNTN2 FCGR2B
5 hereditary neuropathies 30.1 MAG PMP22
6 chronic inflammatory demyelinating polyradiculoneuropathy 29.8 ALB PMP22
7 polyradiculoneuropathy 29.7 ALB PMP22
8 peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease 12.6
9 subacute inflammatory demyelinating polyneuropathy 12.2
10 guillain-barre syndrome, familial 11.8
11 charcot-marie-tooth disease, axonal, type 2e 11.2
12 canomad syndrome 11.0
13 neuropathy 10.5
14 nerve compression syndrome 10.4 PMP22 TTR
15 autoimmune disease of central nervous system 10.3 CNTN1 NFASC
16 chronic pulmonary heart disease 10.3 HP TTR
17 brown-sequard syndrome 10.3 AIF1 TTR
18 paramyloidosis 10.3 ALB TTR
19 burns 10.2 ALB TTR
20 marasmus 10.2 ALB TTR
21 hepatitis 10.2
22 kwashiorkor 10.2 ALB TTR
23 chronic polyneuropathy 10.2 FCGR2B MAG
24 decubitus ulcer 10.2 ALB TTR
25 aleutian mink disease 10.2 ALB TTR
26 chronic ulcer of skin 10.2 ALB TTR
27 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.2
28 carotenemia 10.2 APOA4 TTR
29 hyperthyroxinemia 10.2 ALB TTR
30 myasthenia gravis 10.1
31 poems syndrome 10.1
32 myasthenia gravis congenital 10.1
33 charcot-marie-tooth disease 10.1
34 diabetes mellitus 10.1
35 lymphoma 10.1
36 tooth disease 10.1
37 melanoma 10.1
38 lupus erythematosus 10.1
39 autoimmune neuropathy 10.1 CNTN1 MAG NFASC
40 analbuminemia 10.1 ALB TTR
41 multiple sclerosis 10.1
42 systemic lupus erythematosus 10.1
43 hepatitis b 10.1
44 episodic pain syndrome, familial, 1 10.0
45 hepatitis c 10.0
46 dysentery 10.0 ALB HP TTR
47 testicular yolk sac tumor 10.0 ALB HP TTR
48 protein-energy malnutrition 10.0 ALB TTR
49 hepatitis c virus 10.0
50 glomerulonephritis 10.0

Graphical network of the top 20 diseases related to Demyelinating Polyneuropathy:



Diseases related to Demyelinating Polyneuropathy

Symptoms & Phenotypes for Demyelinating Polyneuropathy

MGI Mouse Phenotypes related to Demyelinating Polyneuropathy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 PMP22 APOA4 PTGDS CNTN1 CNTN2 FCGR2B
2 homeostasis/metabolism MP:0005376 9.85 ALB APOA4 PTGDS TTR FCGR2B HP
3 mortality/aging MP:0010768 9.61 ALB PMP22 APOA4 PTGDS CNTN1 FCGR2B
4 nervous system MP:0003631 9.32 APOA4 PTGDS CNTN1 CNTN2 FCGR2B MAG

Drugs & Therapeutics for Demyelinating Polyneuropathy

Drugs for Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
2 gamma-Globulins Phase 4,Phase 3,Phase 2
3 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
4 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2
5 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2
6
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
7
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
8
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
9 tannic acid Approved, Nutraceutical Phase 3
10 Anti-Inflammatory Agents Phase 3
11 Antineoplastic Agents, Hormonal Phase 3
12 glucocorticoids Phase 3
13 Hormone Antagonists Phase 3,Phase 2
14 Hormones Phase 3,Phase 2
15 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
16 3,4-diaminopyridine Phase 3
17 Potassium Channel Blockers Phase 3
18 Pharmaceutical Solutions Phase 3
19
rituximab Approved Phase 2 174722-31-7 10201696
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
21 Antioxidants Phase 2
22 Micronutrients Phase 2
23 Protective Agents Phase 2
24 Thioctic Acid Phase 2
25 Trace Elements Phase 2
26 Vitamin B Complex Phase 2
27 Vitamins Phase 2
28 Antibodies, Monoclonal Phase 2
29 Antirheumatic Agents Phase 2
30 Fibrinolytic Agents Phase 2
31 Plasminogen Phase 2
32 Tissue Plasminogen Activator Phase 2
33 Alpha-lipoic Acid Nutraceutical Phase 2
34 Folate Nutraceutical Phase 2
35 Vitamin B9 Nutraceutical Phase 2
36 Adjuvants, Immunologic
37 Anti-Bacterial Agents
38 Antibiotics, Antitubercular
39 Anti-Infective Agents
40 Antiviral Agents
41 Interferon Inducers
42 interferons
43 Krestin
44 Radiation-Protective Agents
45 Antibodies, Anti-Idiotypic

Interventional clinical trials:

(show all 39)

# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Recruiting NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
3 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
4 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
5 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
6 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
7 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
8 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
9 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
10 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
11 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
12 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
13 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Recruiting NCT02638207 Phase 3 NewGam
14 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
15 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
16 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
17 Rituximab to Treat Neuropathy With Anti-MAG Antibodies Completed NCT00050245 Phase 2 Rituximab
18 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Recruiting NCT02967679 Phase 1, Phase 2 MD1003
19 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Recruiting NCT02282514 Phase 1, Phase 2
20 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
21 Thrombolysis in Ischemic Spinal Cord Stroke Active, not recruiting NCT02242084 Phase 2 Intravenuse Alteplase
22 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
23 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
24 Effects of an Intervention Program by Proprioceptive Neuromuscular Facilitation, in Muscle Force Irradiation. Unknown status NCT02255708 Phase 1
25 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
26 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
27 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
28 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678
29 Prevalence of Genetic Mutations in Patients With Neuropathy Associated With Anti-Myelin-associated Glycoprotein (MAG) Antibodies Completed NCT03268161
30 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
31 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
32 Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC) Completed NCT03460951
33 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Recruiting NCT02414490 Intravenous Immunoglobulin
34 Low Level Laser Therapy Effects in Peripheral Nerves Patient With Leprosy. Recruiting NCT03072004
35 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology Recruiting NCT03373370
36 Subcutaneous Immunoglobulin for CIDP Active, not recruiting NCT02465359 Immune Globulin Subcutaneous (Human)
37 Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuro Not yet recruiting NCT03008733
38 Quantification of Nerve Stiffness in Neuropathies Not yet recruiting NCT03397303
39 Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome Terminated NCT00004833 Immune globulin

Search NIH Clinical Center for Demyelinating Polyneuropathy

Genetic Tests for Demyelinating Polyneuropathy

Anatomical Context for Demyelinating Polyneuropathy

MalaCards organs/tissues related to Demyelinating Polyneuropathy:

38
T Cells, Spinal Cord, Brain, B Cells, Skin, Endothelial, Tongue

Publications for Demyelinating Polyneuropathy

Articles related to Demyelinating Polyneuropathy:

(show top 50) (show all 702)
# Title Authors Year
1
Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment. ( 29179036 )
2018
2
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab. ( 29382383 )
2018
3
Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. ( 29182448 )
2018
4
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. ( 29122523 )
2018
5
Standing postural reaction to visual and proprioceptive stimulation in chronic acquired demyelinating polyneuropathy. ( 29313871 )
2018
6
Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. ( 29341326 )
2018
7
Elevated serum levels of endothelin-1 in patients with chronic inflammatory demyelinating polyneuropathy. ( 29137897 )
2018
8
Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years. ( 29398193 )
2018
9
Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. ( 29122522 )
2018
10
Vestibular impairment in chronic inflammatory demyelinating polyneuropathy. ( 29260355 )
2018
11
Myasthenia gravis and chronic inflammatory demyelinating polyneuropathy in the same patientA -A a case report. ( 29073825 )
2017
12
Unconventional treatments for chronic inflammatory demyelinating polyneuropathy. ( 29043889 )
2017
13
Chronic inflammatory demyelinating polyneuropathy. ( 28763304 )
2017
14
Chronic Inflammatory Demyelinating Polyneuropathy Variant with Creatine-Kinase Elevation and Vanishing Effect of Immunoglobulins. ( 28747620 )
2017
15
A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy. ( 28485075 )
2017
16
Paranodal dissection in chronic inflammatory demyelinating polyneuropathy with antineurofascin-155 and anticontactin-1 antibodies. ( 28073817 )
2017
17
Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. ( 28768822 )
2017
18
Changes in spatiotemporal gait parameters following intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy. ( 28085193 )
2017
19
Acute Demyelinating Polyneuropathy as Presentation of Hereditary Neuropathy With Liability to Pressure Palsies in a Patient Who Exercised Regularly in the Army. ( 28538254 )
2017
20
Chronic Inflammatory Demyelinating Polyneuropathy: A Case Series. ( 29143254 )
2017
21
Transcranial Magnetic Stimulation as an Additional Diagnostic Tool in Children with Acute Inflammatory Demyelinating Polyneuropathy. ( 28904571 )
2017
22
ELectron microscopic abnormality and therapeutic efficacy in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin155 immunoglobulin G4 antibody. ( 28796305 )
2017
23
Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis. ( 29053880 )
2017
24
The Prevalence and Severity of Autonomic Dysfunction in Chronic Inflammatory Demyelinating Polyneuropathy. ( 28904461 )
2017
25
Chronic inflammatory demyelinating polyneuropathy and malignancy: A systematic review. ( 29194677 )
2017
26
Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study. ( 28000311 )
2017
27
Utility of Neurological Imaging in Sensory Variant of Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. ( 28221307 )
2017
28
Diagnostic Value of the Near-Nerve Needle Sensory Nerve Conduction in Sensory Inflammatory Demyelinating Polyneuropathy. ( 28796344 )
2017
29
Electrodiagnostic misdiagnosis of chronic inflammatory demyelinating polyneuropathy: What are the problems? and how to right the wrongs. ( 29193155 )
2017
30
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): An Uncommon Manifestation of Systemic Lupus Erythematosus (SLE). ( 28894082 )
2017
31
Nodopathy: chronic inflammatory demyelinating polyneuropathy with anti-neurofascin 155 antibodies. ( 28108521 )
2017
32
The medial plantar sensory response: A sensitive marker of acute Inflammatory demyelinating polyneuropathy. ( 28934625 )
2017
33
Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic Accuracy and Correlation With Electrophysiology. ( 28574858 )
2017
34
Acute simultaneous development of brain tumour-like lesion and demyelinating polyneuropathy in a patient with chronic relapsing myelitis. ( 28795610 )
2017
35
Quantitative muscle ultrasound is useful for evaluating secondary axonal degeneration in chronic inflammatory demyelinating polyneuropathy. ( 29075571 )
2017
36
Anti-Ma2-associated limbic encephalitis with coexisting chronic inflammatory demyelinating polyneuropathy in a patient with non-Hodgkin lymphoma: A case report. ( 28984777 )
2017
37
Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. ( 28575198 )
2017
38
Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy. ( 28345260 )
2017
39
Charcot-Marie-Tooth disease type 2 caused by homozygous MME gene mutation superimposed by chronic inflammatory demyelinating polyneuropathy. ( 28855494 )
2017
40
Acute demyelinating polyneuropathy induced by nivolumab. ( 28844069 )
2017
41
Neuromuscular ultrasound findings in distal acquired demyelinating symmetric variant of chronic inflammatory demyelinating polyneuropathy. ( 28667663 )
2017
42
Acute-onset chronic inflammatory demyelinating polyneuropathy after Zika virus infection. ( 29175895 )
2017
43
Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series. ( 28480635 )
2017
44
Demyelinating polyneuropathy in a case of anti-LGI1 encephalitis. ( 28073143 )
2017
45
Role of "Sural Sparing" Pattern (Absent/Abnormal Median and Ulnar with Present Sural SNAP) Compared to Absent/Abnormal Median or Ulnar with Normal Sural SNAP in Acute Inflammatory Demyelinating Polyneuropathy. ( 29085327 )
2017
46
Lumbar plexus in patients with chronic inflammatory demyelinating polyneuropathy: Evaluation with 3D nerve-sheath signal increased with inked rest-tissue rapid acquisition of relaxation enhancement imaging (3D SHINKEI). ( 28668438 )
2017
47
Gastroduodenal Burkitt Lymphoma Presenting as Demyelinating Polyneuropathy. ( 28532696 )
2017
48
Postural tremor and chronic inflammatory demyelinating polyneuropathy. ( 27421831 )
2016
49
Acute-onset chronic inflammatory demyelinating polyneuropathy in hantavirus and hepatitis B virus coinfection: A case report. ( 27930572 )
2016
50
Evaluation of Patients with Refractory Chronic Inflammatory Demyelinating Polyneuropathy. ( 27463215 )
2016

Variations for Demyelinating Polyneuropathy

Expression for Demyelinating Polyneuropathy

Search GEO for disease gene expression data for Demyelinating Polyneuropathy.

Pathways for Demyelinating Polyneuropathy

Pathways related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.79 CNTN2 MAG NFASC NGF
2
Show member pathways
11.43 CNTN1 CNTN2 NFASC
3 11.09 CNTN1 CNTN2 MAG NFASC
4 10.9 ALB TTR

GO Terms for Demyelinating Polyneuropathy

Cellular components related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.5 ALB APOA4 HP
2 node of Ranvier GO:0033268 9.26 CNTN2 NFASC
3 paranode region of axon GO:0033270 9.16 MAG NFASC
4 myelin sheath GO:0043209 9.02 ALB CNTN1 CNTN2 MAG NFASC
5 compact myelin GO:0043218 8.96 MAG PMP22

Biological processes related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.71 CNTN1 CNTN2 MAG NFASC
2 cellular protein metabolic process GO:0044267 9.54 ALB APOA4 TTR
3 receptor-mediated endocytosis GO:0006898 9.5 ALB FCGR2B HP
4 peripheral nervous system development GO:0007422 9.26 NFASC PMP22
5 high-density lipoprotein particle remodeling GO:0034375 9.16 ALB APOA4
6 central nervous system myelination GO:0022010 8.96 CNTN2 MAG
7 protein localization to juxtaparanode region of axon GO:0071205 8.62 CNTN2 NFASC

Molecular functions related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.33 CNTN1 CNTN2 MAG
2 fatty acid binding GO:0005504 8.96 ALB PTGDS
3 antioxidant activity GO:0016209 8.8 ALB APOA4 HP

Sources for Demyelinating Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....